bupropion has been researched along with liraglutide in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 16 (69.57) | 24.3611 |
2020's | 7 (30.43) | 2.80 |
Authors | Studies |
---|---|
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J | 1 |
Nakazato, M; Ueno, H | 1 |
Aldhoon-Hainerová, I; Hainer, V | 1 |
Hainer, V | 1 |
Aronne, LJ | 1 |
Fujioka, K | 1 |
Howland, RH | 1 |
Bragg, R; Crannage, E | 1 |
Megyeri, J; Nuffer, W; Trujillo, JM | 1 |
Braverman-Panza, J; Fujioka, K | 1 |
Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH | 1 |
Curry, SA | 1 |
Bersoux, S; Byun, TH; Chaliki, SS; Poole, KG | 1 |
Wilding, JPH | 1 |
Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M | 1 |
Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K | 1 |
Capasso, A; De Biasio, V; Di Munzio, W; Foggia, G; Milano, W | 1 |
Barrea, L; Colao, A; Laudisio, D; Muscogiuri, G; Pugliese, G; Savastano, S | 1 |
Brown, SA; Izzy, M; Watt, KD | 1 |
Lee, SY; Tak, YJ | 1 |
Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS | 1 |
Hill, A; Levi, J; Venter, F; Wang, J | 1 |
Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K | 1 |
16 review(s) available for bupropion and liraglutide
Article | Year |
---|---|
Recent advancements in drug treatment of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss | 2012 |
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate | 2014 |
Tolerability and safety of the new anti-obesity medications.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate | 2014 |
Overview of new antiobesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2014 |
Evolving directions in obesity management.
Topics: Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Forecasting; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Liraglutide; Naltrexone; Narcotic Antagonists; Obesity; Receptors, Glucagon | 2014 |
Safety and tolerability of medications approved for chronic weight management.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2015 |
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesity; Psychotropic Drugs; Weight Gain | 2015 |
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2016 |
Practical Use of Pharmacotherapy for Obesity.
Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain | 2017 |
Pharmacotherapy for obesity: What you need to know.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine | 2017 |
Gender-related issues in the pharmacology of new anti-obesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Liraglutide; Male; Naltrexone; Obesity; Patient Selection; Sex Factors; Topiramate; Treatment Outcome; Weight Loss | 2019 |
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Liraglutide; Naltrexone; Obesity; Orlistat; Polycystic Ovary Syndrome; Weight Loss | 2018 |
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Precision Medicine; Weight Loss | 2020 |
New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Endocrinology; Humans; Liraglutide; Naltrexone; Nutritional Sciences; Obesity | 2020 |
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical | 2021 |
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2021 |
7 other study(ies) available for bupropion and liraglutide
Article | Year |
---|---|
Review of pharmacotherapy options for the management of obesity.
Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States | 2016 |
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Primary Health Care; Risk Factors; Treatment Outcome; Weight Loss | 2016 |
Obesity Epidemic: Pharmaceutical Weight Loss.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss | 2017 |
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans; Life Style; Liraglutide; Naltrexone; Obesity; Primary Health Care; Specialization; State Medicine; United Kingdom; Weight Loss; Weight Reduction Programs | 2018 |
[Pharmacotherapy for obesity].
Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Humans; Hunger; Life Style; Liraglutide; Naltrexone; Obesity; Satiation; Treatment Outcome; Weight Loss | 2021 |
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Health Care Costs; Health Services Accessibility; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate | 2023 |
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long
Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Liraglutide; Naltrexone; Obesity; Overweight; Peptides; Proglucagon; Weight Loss | 2023 |